Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We have pursued an approach of complete resection for patients with gastrointestinal stromal tumors (GISTs), including multivisceral resection, for patients with disease involving adjacent organs. We have also extended the limits of resection to include patients with metastatic disease who were treated with imatinib mesylate. The aim of this study is to report the outcomes and prognostic factors associated with this clinical approach. Study subjects were identified using the pathology database at our institution; for inclusion in the study group, patients must have undergone surgical resection for a KIT-positive gastrointestinal stromal tumor between January 1992 and March 2004. We calculated survival by using the Kaplan-Meier method. Univariate and multivariate analysis was performed using log-rank analysis and the Cox proportional hazards model. Thirty-four patients met the study criteria. Fifty-nine percent of patients had GISTs of gastric origin, 20.6% had duodenal GISTs, and the remainder was comprised of a variety of other sites. Twenty-two (64.7%) patients underwent single-organ resection, and 12 patients (35.3%) underwent multivisceral resection. Estimated actuarial survival at 5 years was 65.2%. Seven patients (five patients with metastases, one patient with locally advanced disease, and one patient with organ-confined disease) received imatinib mesylate. Independent predictors of poor survival included incomplete resection, metastatic disease at presentation, and high mitotic index. Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival.

Original languageEnglish (US)
Pages (from-to)1099-1105
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume10
Issue number8
DOIs
StatePublished - Sep 2006

Fingerprint

Gastrointestinal Stromal Tumors
Therapeutics
Survival
Mitotic Index
Neoplasm Metastasis
Proportional Hazards Models
Stomach
Multivariate Analysis

Keywords

  • Gastrointestinal stromal tumors
  • gastrointestinal tract
  • imatinib mesylate
  • KIT

ASJC Scopus subject areas

  • Surgery

Cite this

Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors. / Gupta, Maneesh; Sheppard, Brett; Corless, Christopher; MacDonell, Karen R.; Blanke, Charles; Billingsley, Kevin.

In: Journal of Gastrointestinal Surgery, Vol. 10, No. 8, 09.2006, p. 1099-1105.

Research output: Contribution to journalArticle

@article{988478f010414184a28fdfdce4597199,
title = "Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors",
abstract = "We have pursued an approach of complete resection for patients with gastrointestinal stromal tumors (GISTs), including multivisceral resection, for patients with disease involving adjacent organs. We have also extended the limits of resection to include patients with metastatic disease who were treated with imatinib mesylate. The aim of this study is to report the outcomes and prognostic factors associated with this clinical approach. Study subjects were identified using the pathology database at our institution; for inclusion in the study group, patients must have undergone surgical resection for a KIT-positive gastrointestinal stromal tumor between January 1992 and March 2004. We calculated survival by using the Kaplan-Meier method. Univariate and multivariate analysis was performed using log-rank analysis and the Cox proportional hazards model. Thirty-four patients met the study criteria. Fifty-nine percent of patients had GISTs of gastric origin, 20.6{\%} had duodenal GISTs, and the remainder was comprised of a variety of other sites. Twenty-two (64.7{\%}) patients underwent single-organ resection, and 12 patients (35.3{\%}) underwent multivisceral resection. Estimated actuarial survival at 5 years was 65.2{\%}. Seven patients (five patients with metastases, one patient with locally advanced disease, and one patient with organ-confined disease) received imatinib mesylate. Independent predictors of poor survival included incomplete resection, metastatic disease at presentation, and high mitotic index. Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival.",
keywords = "Gastrointestinal stromal tumors, gastrointestinal tract, imatinib mesylate, KIT",
author = "Maneesh Gupta and Brett Sheppard and Christopher Corless and MacDonell, {Karen R.} and Charles Blanke and Kevin Billingsley",
year = "2006",
month = "9",
doi = "10.1016/j.gassur.2006.05.014",
language = "English (US)",
volume = "10",
pages = "1099--1105",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors

AU - Gupta, Maneesh

AU - Sheppard, Brett

AU - Corless, Christopher

AU - MacDonell, Karen R.

AU - Blanke, Charles

AU - Billingsley, Kevin

PY - 2006/9

Y1 - 2006/9

N2 - We have pursued an approach of complete resection for patients with gastrointestinal stromal tumors (GISTs), including multivisceral resection, for patients with disease involving adjacent organs. We have also extended the limits of resection to include patients with metastatic disease who were treated with imatinib mesylate. The aim of this study is to report the outcomes and prognostic factors associated with this clinical approach. Study subjects were identified using the pathology database at our institution; for inclusion in the study group, patients must have undergone surgical resection for a KIT-positive gastrointestinal stromal tumor between January 1992 and March 2004. We calculated survival by using the Kaplan-Meier method. Univariate and multivariate analysis was performed using log-rank analysis and the Cox proportional hazards model. Thirty-four patients met the study criteria. Fifty-nine percent of patients had GISTs of gastric origin, 20.6% had duodenal GISTs, and the remainder was comprised of a variety of other sites. Twenty-two (64.7%) patients underwent single-organ resection, and 12 patients (35.3%) underwent multivisceral resection. Estimated actuarial survival at 5 years was 65.2%. Seven patients (five patients with metastases, one patient with locally advanced disease, and one patient with organ-confined disease) received imatinib mesylate. Independent predictors of poor survival included incomplete resection, metastatic disease at presentation, and high mitotic index. Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival.

AB - We have pursued an approach of complete resection for patients with gastrointestinal stromal tumors (GISTs), including multivisceral resection, for patients with disease involving adjacent organs. We have also extended the limits of resection to include patients with metastatic disease who were treated with imatinib mesylate. The aim of this study is to report the outcomes and prognostic factors associated with this clinical approach. Study subjects were identified using the pathology database at our institution; for inclusion in the study group, patients must have undergone surgical resection for a KIT-positive gastrointestinal stromal tumor between January 1992 and March 2004. We calculated survival by using the Kaplan-Meier method. Univariate and multivariate analysis was performed using log-rank analysis and the Cox proportional hazards model. Thirty-four patients met the study criteria. Fifty-nine percent of patients had GISTs of gastric origin, 20.6% had duodenal GISTs, and the remainder was comprised of a variety of other sites. Twenty-two (64.7%) patients underwent single-organ resection, and 12 patients (35.3%) underwent multivisceral resection. Estimated actuarial survival at 5 years was 65.2%. Seven patients (five patients with metastases, one patient with locally advanced disease, and one patient with organ-confined disease) received imatinib mesylate. Independent predictors of poor survival included incomplete resection, metastatic disease at presentation, and high mitotic index. Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival.

KW - Gastrointestinal stromal tumors

KW - gastrointestinal tract

KW - imatinib mesylate

KW - KIT

UR - http://www.scopus.com/inward/record.url?scp=33748457495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748457495&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2006.05.014

DO - 10.1016/j.gassur.2006.05.014

M3 - Article

C2 - 16966028

AN - SCOPUS:33748457495

VL - 10

SP - 1099

EP - 1105

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 8

ER -